A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

September 1, 2022

Study Completion Date

March 10, 2023

Conditions
Sjögren's Syndrome
Interventions
DRUG

VIB4920

Intravenous Dose 1.

DRUG

Placebo

Intravenous dose matched to VIB4920.

Trial Locations (62)

1

Research Site, Lima

31

Research Site, Lima

33

Research Site, Lima

1097

Research Site, Budapest

4032

Research Site, Debrecen

5700

Research Site, Gyula

16499

Research Site, Suwon

16635

Research site, Duncansville

20122

Research Site, Milan

20902

Research Site, Wheaton

21224

Research Site, Baltimore

21565

Research Site, Incheon

22332

Research Site, Incheon

25000

Research Site, Saltillo

25123

Research Site, Brescia

27710

Research Site, Durham

28144

Research Site, Salisbury

28204

Research Site, Charlotte

28401

Research Site, Wilmington

30046

Research Site, Lawrenceville

33100

Research Site, Udine

38119

Research Site, Memphis

40705

Research Site, Taichung

44650

Research Site, Guadalajara

44690

Research Site, Guadalajara

56126

Research Site, Pisa

66160

Research Site, Kansas City

75231

Research site, Dallas

77084

Research Site, Houston

77089

Research Site, Houston

81362

Research Site, Kaohsiung City

91786

Research site, Upland

92835

Research Site, Fullerton

380015

Research Site, Ahmedabad

411001

Research Site, Pune

411013

Research Site, Pune

560010

Research Site, Bangalore

600004

Research Site, Chennai

751005

Research Site, Bhubaneswar

5000003

Research Site, Secunderabad

02111

Research Site, Boston

C1114AAH

Research Site, Ciudad Autonoma de Buenos Aires

Unknown

Research Site, Bordeaux

Research Site, Brest

Research Site, Grenoble

Research Site, Paris

Research Site, Strasbourg

00161

Research Site, Rome

06129

Research Site, Perugia

06700

Research Site, Mexico City

82-300

Research Site, Elblag

30-363

Research Site, Krakow

20-412

Research Site, Lublin

60-693

Research Site, Poznan

08-110

Research Site, Siedlce

71-252

Research Site, Szczecin

02-637

Research Site, Warsaw

Research Site, Wroclaw

02-691

Research Site, Warsaw

06591

Research Site, Seoul

NE1 4LP

Research Site, Newcastle upon Tyne

TR13LJ

Research Site, Truro

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY